Articles From: Oncolytics Biotech® Inc. Announces Third Quarter 2014 Results to Oncothyreon to Present at Stifel 2014 Healthcare Conference


2014/11/6
CALGARY , Nov.
Sign-up for Oncolytics Biotech® Inc. Announces Third Quarter 2014 Results investment picks
REDWOOD CITY, Calif., Jan.
Sign-up for OncoMed Doses First Patient in Phase 1 Clinical Trial of Novel Anti-DLL4/VEGF Bispecific Antibody investment picks
Raises Year-End Cash Balance Guidance to Over $225 Million From $215 Million REDWOOD CITY, Calif., Nov.
Sign-up for OncoMed Pharmaceuticals Announces Third Quarter 2014 Financial and Operating Results investment picks
REDWOOD CITY, Calif., Nov.
Sign-up for OncoMed Pharmaceuticals Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent in the U.S. investment picks
REDWOOD CITY, Calif., Nov.
Sign-up for OncoMed Pharmaceuticals to Present at Piper Jaffray Healthcare Conference investment picks
REDWOOD CITY, Calif., Oct.
Sign-up for OncoMed Pharmaceuticals to Present at the 13th Annual BIO Investor Forum investment picks
REDWOOD CITY, Calif., Jan.
Sign-up for OncoMed Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
Begins 2015 with $232 Million in Cash Potential Milestones from Existing Partnerships in 2015/2016 Projected at Over $150 Million REDWOOD CITY, Calif., Jan.
Sign-up for OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance investment picks
BARCELONA, Spain and REDWOOD CITY, Calif., Nov.
Sign-up for OncoMed Presents Biomarker-Focused Clinical Data From Phase 1a Trial of Anti-Notch1 (OMP-52M51) in Oral Plenary Session at the 26th EORTC-NCI-AACR Symposium investment picks
Median Overall Survival of 14.6 Months in Tumor Notch3 High Patients and 11.6 Months in All Patients REDWOOD CITY, Calif., Jan.
Sign-up for OncoMed Presents Final Phase 1b Safety, Efficacy and Biomarker Data for Tarextumab in Pancreatic Cancer at the 2015 Gastrointestinal Cancer Symposium investment picks
Biomarker Studies Demonstrate On-Target Effects of Tarextumab Against Notch Pathway and Cancer Stem Cells in Patients With Pancreatic Cancer Patient-Derived Preclinical and Clinical Data Support the Phase 2 Development of Demcizumab With Abraxane and Gemcitabine in Pancreatic Cancer  BARCELONA, Spain and REDWOOD CITY, Calif., Nov.
Sign-up for OncoMed Presents New Clinical and Biomarker Data From Its Tarextumab and Demcizumab Clinical Trials at the EORTC-NCI-AACR Symposium investment picks
NEWTOWN, Pa., Dec.
Sign-up for Onconova Announces ONTIME Data Presentations at the 2014 ASH Annual Meeting investment picks
--Phase 3 ONTIME Trial Data Selected for Oral Presentation--
Sign-up for Onconova Announces Ten Presentations at the 2014 ASH Annual Meeting investment picks
NEWTOWN, Pa., Jan.
Sign-up for Onconova Therapeutics Appoints Dr. Steven M. Fruchtman as Chief Medical Officer investment picks
NEWTOWN, Pa., Dec.
Sign-up for Onconova Therapeutics to Host Analyst Event in New York City on December 12, 2014 investment picks
OncoSec Medical Inc. (OTCQB: ONCS ), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the quarter ended October 31, 2014.
Sign-up for OncoSec Medical Announces First Quarter Results for Fiscal Year End 2015 investment picks
SEATTLE, Nov.
Sign-up for Oncothyreon Reports Third Quarter 2014 Financial Results investment picks
SEATTLE, Nov.
Sign-up for Oncothyreon to Present at Stifel 2014 Healthcare Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Oncolytics Biotech® Inc. Announces Third Quarter 2014 Results to Oncothyreon to Present at Stifel 2014 Healthcare Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent